Regentis Biomaterials Secures Japanese Patent, Bolstering Global IP and Manufacturing for GelrinC

As aging populations drive joint diseases up the orthopedic agenda, cartilage damage remains one of the field's largest unmet needs. Current treatments have shown clinical utility, but they are often difficult to deliver efficiently and economically at scale. This gap highlights the value of off-the-shelf therapies, where manufacturing expertise and intellectual property are as crucial as clinical performance. Regentis Biomaterials (NYSE American: RGNT) is addressing this need with GelrinC, a cell-free hydrogel for knee cartilage repair, administered in a single procedure of about 10 minutes without cell harvesting or laboratory processing.

On July 20, the company announced a new patent allowance from the Japan Patent Office, following a recent US patent grant. This strengthens protection around its organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending its intellectual property footprint into one of the world's largest cartilage-repair markets. The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, providing the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale.

The milestone arrives as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal US trial. The enhanced IP portfolio is expected to support the global rollout of GelrinC, positioning the company to capitalize on the growing demand for minimally invasive cartilage repair solutions.

For more information on the company's latest updates, visit its newsroom at https://ibn.fm/RGNT. The full terms of use and disclaimers can be found at http://IBN.fm/Disclaimer.

This announcement underscores the importance of robust IP and manufacturing innovation in the medical device sector, particularly for products aiming to address widespread clinical needs efficiently.